CRISPR Therapeutics' GAAP net income for 2021 was $377.661 million, compared to a loss of $348.865 million the previous year. Revenue increased multiple times to $914.963 million from $0.719 million a year earlier.
CRISPR Therapeutics' GAAP net income for 2021 was $377.661 million, compared to a loss of $348.865 million the previous year. Revenue increased multiple times to $914.963 million from $0.719 million a year earlier. 
ir.crisprtx.com
English (US) 